Expanding the antigenic repertoire of BCG improves protective efficacy against aerosolMycobacterium tuberculosisinfection

We have developed a strain of the tuberculosis vaccineMycobacterium bovisbacille Calmette Guérin (BCG) that secretes high levels of a fusion protein comprising the immunodominantMycobacterium tuberculosisAg85B and ESAT-6 (BCG85B-ES). Mice vaccinated with BCG85B-ESwere significantly better protected...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 23; no. 14; p. 1680
Main Authors Palendira, Umaimainthan, Spratt, Joanne M, Britton, Warwick J, Triccas, James A
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Limited 25.02.2005
Subjects
Bacteria
Cloning
Deoxyribonucleic acid
DNA
Experiments
Gene expression
Immunization
Infections
Laboratories
Lymphocytes
Proteins
R&D
Research & development
Spleen
Statistical analysis
Tuberculosis
Vaccines
Variance analysis
Online AccessGet full text

Cover

More Information
Summary:We have developed a strain of the tuberculosis vaccineMycobacterium bovisbacille Calmette Guérin (BCG) that secretes high levels of a fusion protein comprising the immunodominantMycobacterium tuberculosisAg85B and ESAT-6 (BCG85B-ES). Mice vaccinated with BCG85B-ESwere significantly better protected in the lung against aerosol infection with virulentM. tuberculosisthan animals immunized with control BCG. The growth characteristic of BCG85B-ESin host tissue was identical to control BCG, suggesting the improved protective efficacy was directly related to the expression of the Ag85B-ESAT-6 fusion protein. These results suggest that BCG85B-ESwarrants further investigation to determine its suitability to control tuberculosis in humans.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2004.10.007